

The Board:

1. *Approves the incremental funding recommended for each country and regional disease component, and its constituent grants, as listed in Table 1a and 1b, respectively, of Section IV to GF/B35/ER11 (collectively, "Table 1");*
2. *Acknowledges each country and regional disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;*
3. *Approves the reinvestment of within-allocation efficiencies for the Zambia TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B35/ER11;*
4. *Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DPO5 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;*
5. *Approves the additional incremental funding and implementation period recommended for the Philippines TB disease component, being an Early Applicant grant, as listed in Table 3 of Section IV to GF/B35/ER11, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DPO2;*
6. *Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country and regional disease component's constituent grants, (b) is subject to the availability of funding and (c) shall be committed in annual tranches; and*
7. *Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country and regional disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.*

Table 1a: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Country Applicants)

N	Applicant	Disease component	Proposed Principal Recipient (Grant Name)	Grant End Date	Currency	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
							Existing Funding	Recommended Incremental Funding				
1	Bolivia	HIV/AIDS	BOL-H-HIVOS	31 December 2018	US\$	8,300,760	374,111	7,926,649	7,926,649	0	1,784,691	26.8 million
2	Central African Republic ¹	TB/HIV	CAF-C-IFRC	31 December 2017	€	16,050,093	5,115,291	10,934,802	10,934,802	n/a	4,325,179	3.6 million
3	Côte D'Ivoire ¹	HIV/AIDS	CIV-910-G12-H	31 December 2017	€	82,330,016	61,095,017	4,564,865	9,420,893	n/a	0	27.7 million
			CIV-910-G13-H	31 December 2017			11,814,105	4,856,028				
4	Georgia	TB	GEO-T-NCDC	31 December 2019	US\$	12,921,440	8,143,021	4,778,419	4,778,419	0	0	23.3 million

¹ The Central African Republic TB/HIV, Cote D'Ivoire HIV, Guatemala HIV, Namibia HIV and Sao Tome and Principe HIV grants followed a simplified application approach with no material reprogramming.

5	Guatemala ¹	HIV/AIDS	GUA-311- GO5H	31 December 2017	US\$	15,433,485	5,554,638	2,487,913	6,300,000	n/a	0	31.7 million
			GUA-311- GO6H	31 December 2017			3,578,847	3,812,087				
6	Honduras	TB	HND-T- UAFCE	31 December 2019	US\$	6,837,592	2,731,323	4,106,269	4,106,269	0	0	6.99 million
7	Mali ²	TB/HIV	MLI-H- PLAN	31 December 2017	€	6,660,828	0	6,660,828	6,660,828	0	0	11.2 million
8	Morocco	HSS	MAR-S- MOH	31 August 2019	€	6,143,816	312,190	5,831,626	5,831,626	0	0	86 million ³
9	Namibia ¹	HIV/AIDS	NMB-202- Go1-H	31 December 2017	US\$	57,549,648	46,882,391	116,827	116,827	n/a	0	290 million
			NMB-202- Go7-H	31 December 2017			10,550,430	0				
10	Sao Tome and Principe ¹	HIV/AIDS	STP-H- UNDP	31 March 2018	US\$	645,455	387,135	258,320	258,320	n/a	0	4.1 million

² As part of the Mali TB/HIV program, the Mali HIV grant MLI-H-UNDP with UNDP as Principal Recipient was approved for funding in December 2015 and the Mali TB grant MLI-T-CRS with Catholic Relief Services as Principal Recipient was approved for funding in January 2016. The grant currently being recommended for financing is a complementary grant with PLAN as implementer.

³ This amount is reflected in US dollars, based on government commitment.

Table 1b: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Regional Applicants)

N	Applicant	Disease component	Currency	Grant name	Grant end date	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic commitment
							Existing funding	Incremental amount for Board approval				
1	CVC/COIN	HIV/AIDS	US\$	QRA-H-UNDP	30 September 2019	7,380,339	0	7,380,339	7,380,339	n/a	0	n/a
2	IGAD	TB/HIV	US\$	QPA-C-IGAD	31 March 2019	10,000,000	0	10,000,000	10,000,000	n/a	0	n/a
3	PANCAP	HIV/AIDS	US\$	QRA-H-CARICOM	30 September 2019	5,075,234	0	5,075,234	5,075,234	n/a	0	n/a
4	ISEAN-HIVOS	HIV/AIDS	US\$	MEI-011-G01-H	31 December 2017	2,249,339	832,920	1,416,419	1,416,419	n/a	n/a	n/a

Table 2: Reinvestment of Within-Allocation Efficiencies for Previously-Approved Programs

N	Applicant	Disease Component	Grant Name	Currency	Period of Extension (Months)	Previously Approved Grant Budget	Revised Budget for Board Approval	Original Existing Funding	Additional Existing Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Total Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
1	Zambia	TB/HIV	ZMB-C-CHAZ	US\$	n/a	57,588,242	60,845,770	16,846,264	3,257,528	40,741,978	0	0	4,914,418

Table 3: Secretariat’s Recommendation on Early Applicants

N	Applicant	Disease Component	Grant Name	Currency	Period of Extension (Months)	Previously Approved Grant Budget	Revised Budget for Board Approval	Original Existing Funding	Additional Existing Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Total Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
1	Philippines	TB	PHL-T-PBSP	US\$	12	90,236,481	108,440,114 ₄	77,536,167	0	12,700,314	25,326,007	25,326,007	5,291,510

⁴ The revised budget reflects the original approved budget amount of US\$90,236,481, the signed budget amount of US\$83,114,107 and the additional incremental funding of US\$25,326,007 recommended by the GAC for Board approval.